Abstract 1886
Background
Knowledge of molecular abnormalities in haematological malignancies led to better understanding of their role in disease development, progression and resistance to treatments. However, effective impact of NGS analyses need to be evaluated. RuBIH2 programme aims to determine appropriate prescription, clinical utility and validity, cost and territorial organisation of NGS under a governmental funded “Programme de Recherche Médico-Economique” (Health Economics Research Program).
Methods
We considered 5 haematological malignancies: myelodysplasia, acute lymphoid leukaemia, acute myeloid leukaemia, lymphoma and lymphoproliferative disorders and myeloproliferative disorders. 26 French biomolecular platforms are involved. The program is split into 4 work packages (WP). WP1: micro-costing, WP2: appropriate prescribing guidelines, WP3: evaluation of clinical validity, WP4: recommendations on national organization.
Results
WP1: is a micro-costing of NGS on 5 biomolecular platforms to assess production cost depending on the volume of analyses performed, type of pathology and panel size. Based on a bottom-up approach and onsite observations, we calculated an average mean cost. WP2: is to define recommended diagnostic tests according to pathologies and patients’ characteristics. National key opinion leaders (clinicians and biologists) defined a NGS minimal panel depending on therapeutic possibilities. Biological analyses performed at diagnosis, relapse or during follow-up will be classified as mandatory, recommended, under evaluation or obsolete. WP3: is a real-world data study of NGS analyses carried out by 26 biomolecular platforms. Biological and clinical information are collected in an eCRF. Analysis will describe the impact of NGS on patients’ pathways. WP4: will integrate data collected during WP 1-3 to define an optimal national organization and bundled payment scheme.
Conclusions
Final objective is to improve patient care and access to NGS based on better stratification and definition of analyses to perform at each stage of patient’s care pathways: diagnostic, relapse and follow-up.
Clinical trial identification
NCT03750994.
Editorial acknowledgement
Legal entity responsible for the study
Assistance Publique Hôpitaux de Paris.
Funding
Direction Générale de l’Offre de Soins (DGOS) - French Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract